Abbott (ABT) call put ratio 2.8 calls to 1 put into quarter results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips below $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
Abbott Labs (ABT) PT Raised to $140 at Evercore ISI
April 16, 2025 11:38 AM EDTEvercore ISI analyst Vijay Kumar raised the price target on Abbott Labs (NYSE: ABT) to $140.00 (from $138.00) while maintaining a Outperform rating.
The analyst comments "Thesis Update: In an environment where uncertainty is the dominating theme, ability to protect bottom-line should be appreciated.... More
Stifel Reiterates Buy Rating on Abbott Labs (ABT)
April 16, 2025 8:47 AM EDTStifel analyst Rick Wise reiterated a Buy rating and $135.00 price target on Abbott Labs (NYSE: ABT).
The analyst comments "From our perspective, Abbott's first quarter report contained few surprises, both to the upside or the downside. First quarter 2025 numbers came in largely in-line with our own projections and Consensus estimates. Reported sales at $10.36B (+6.9% y/y) were in-line with our $10.35B... More
BTIG Reiterates Buy Rating on Abbott Labs (ABT)
April 16, 2025 8:46 AM EDTBTIG analyst Marie Thibault reiterated a Buy rating and $140.00 price target on Abbott Labs (NYSE: ABT).
The analyst comments "With adj. EPS two cents above expectations despite a minor sales miss, we think this was a solid quarter from Abbott. We breathe a sigh of relief to see ABT reaffirm its 2025 guide for sales, adj. operating margin, and adj. EPS. We think this matters most to investors. The company reported Q1 total revenue $10.358B (+6.9 y/y org. and +4.0% y/y rep.) that was ~$50M below consensus of $10.407B. Results were helped... More
